The Indian pharmaceutical market has for the first time crossed the Rs 100000 crore

MUMBAI: The Indian pharmaceutical market has for the first time crossed the Rs 100000 crore mark in November when calculated on the basis of Moving Annual Total (MAT), said IMS Health, a global pharmaceutical market research firm.

In its monthly review of the local market, IMS Health said in its note titled Market Reflections that Indian companies took over three-fourth of the market share during the month.

On an average over the last three years, Indian pharmaceutical market has grown by 12%. Almost 38% of the market was dominated by drugs that treat infections, heart ailments and patients with gastro-intestinal issues. IMS report said in November, Indian market was at Rs 100115 crore, of which the retail sector was valued at Rs 84279 crore.

Sun Pharma remained at the top of the list of drug companies with a market share of 8%, followed by Abbott with a share of 6.1%. Cipla trailed at 5.4% but grew higher than its top peers showing growth of 16% during the month. Mankind Pharma has jumped past its traditional rivals to secure the fourth position with a market share of 3.7%, standing above Alkem, GlaxoSmithKline and Zydus Cadila.

Mixtard, a popular insulin marketed by Abbott, continued to hold the position of the largest brand for the month followed by Pfizer cough syrup Corex and Glycomet-gp, a diabetes brand of USV.

http://articles.economictimes.indiatimes.com/2015-12-16/news/69090998_1_market-share-indian-companies-ims-health